Cited by 24Genetic and Clinical Aspects of Sex Determination and Chromosomal AbnormalitiesSexual Differentiation and DisordersHormonal and reproductive studies

Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome

Open access
Freriks, Kim, Sas, Theo C J, Traas, Maaike A F, Netea-Maier, Romana T, den Heijer, Martin, Hermus, Ad R M M, Wit, Jan M, van Alfen-van der Velden, Janiëlle A E M +7 more·2013·European Journal of Endocrinology

Abstract

OBJECTIVE: Short stature is a prominent feature of Turner syndrome (TS), which is partially overcome by GH treatment. We have previously reported the results of a trial on the effect of oxandrolone (Ox) in girls with TS. Ox in a dose of 0.03 mg/kg per day (Ox 0.03) significantly increased adult height gain, whereas Ox mg/kg per day (0.06) did not, at the cost of deceleration of breast development and mild virilization. The aim of this follow-up study in adult participants of the pediatric trial was to investigate the long-term effects of previous Ox treatment. DESIGN AND METHODS: During the previous randomized controlled trial, 133 girls were treated with GH combined with placebo (Pl), Ox 0.03, or Ox 0.06 from 8 years of age and estrogen from 12 years. Sixty-eight women (Pl, n=23; Ox 0.03, n=27; and Ox 0.06, n=18) participated in the double-blind follow-up study (mean age, 24.0 years; mean time since stopping GH, 8.7 years; and mean time of Ox/Pl use, 4.9 years). We assessed height, body proportions, breast size, virilization, and body composition. RESULTS: Height gain (final minus predicted adult height) was maintained at follow-up (Ox 0.03 10.2±4.9 cm, Ox 0.06 9.7±4.4 cm vs Pl 8.0±4.6 cm). Breast size, Tanner breast stage, and body composition were not different between groups. Ox-treated women reported more subjective virilization and had a lower voice frequency. CONCLUSION: Ox 0.03 mg/kg per day has a beneficial effect on adult height gain in TS patients. Despite previously reported deceleration of breast development during Ox 0.03 treatment, adult breast size is not affected. Mild virilization persists in only a small minority of patients. The long-term evaluation indicates that Ox 0.03 treatment is effective and safe.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-12-0404

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Gerver W. Paediatric Morphometrics. A Reference Manual (second extended edition). Universitaire Pers Maastricht, 2001.

Cited by

Sorted by citations

Authors
Freriks, K., Sas, T. C. J., Traas, M. A. F., Netea-Maier, R. T., den Heijer, M., Hermus, A. R. M. M., Wit, J. M., van Alfen-van der Velden, J. A. E. M., Otten, B. J., de Muinck Keizer-Schrama, S. M. P. F., Gotthardt, M., Dejonckere, P. H., Zandwijken, G. R. J., Menke, L. A., & Timmers, H. J. L. M.
Affiliations
  • Radboud University Medical Center (NL)
  • Erasmus MC (NL)
  • Gelre Hospitals (NL)
  • Leiden University Medical Center (NL)
  • University Medical Center Utrecht (NL)
Corresponding author
Freriks, Kim
Venue
European Journal of Endocrinology
Published
2013-01
Volume
168
Issue
1
Pages
91-99
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2161179909
Cited by
24
References
40
Citations by year
2024: 1 · 2023: 2 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 3 · 2015: 4 · 2014: 3 · 2013: 1
FWCI
1.54
Type
journal article
Language
en
Open access
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
Funders
Pfizer
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
Turner syndrome, oxandrolone, growth hormone therapy, short stature, long-term follow-up, breast development, masculinization, body composition, body proportions, voice frequency, anabolic steroids
MeSH terms
Adult, Body Height, Breast, Child, Child, Preschool, Double-Blind Method, Female, Follow-Up Studies, Humans, Oxandrolone, Turner Syndrome, Virilism, Randomized Controlled Trials as Topic, Treatment Outcome, Human Growth Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review